CA
FLXN

Claro Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Claro Advisors’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,700
Closed -$187K – 299
2021
Q3 		$187K Buy
30,700
+5,850
+24% +$36.5K 0.08% 242
2021
Q2 		$205K Buy
24,850
+100
+0.4% +$850 0.09% 222
2021
Q1 		$222K Hold
24,750
– – 0.11% 193
2020
Q4 		$286K Hold
24,750
– – 0.15% 158
2020
Q3 		$258K Sell
24,750
-400
-2% -$4.9K 0.16% 153
2020
Q2 		$331K Buy
25,150
+150
+0.6% +$1.55K 0.23% 123
2020
Q1 		$197K Buy
25,000
+2,450
+11% +$36.9K 0.18% 147
2019
Q4 		$467K Sell
22,550
-750
-3% -$12.6K 0.36% 85
2019
Q3 		$319K Buy
23,300
+1,200
+5% +$14.2K 0.28% 110
2019
Q2 		$272K Sell
22,100
-50
-0.2% -$577 0.25% 122
2019
Q1 		$276K Buy
22,150
+5,500
+33% +$73.5K 0.27% 117
2018
Q4 		$312K Buy
+16,650
New +$261K 0.25% 93

Claro Advisors's FLXN Position: Q4 2021 in Review

Claro Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 30,700 shares — an estimated $187K sold.

Claro Advisors first reported a position in FLXN in Q4 2018 and held it in 12 quarters. The position peaked at $467K in Q4 2019. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

  • Claro Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Claro Advisors sold 30,700 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $187K.
  • Claro Advisors first reported a position in Flexion Therapeutics, Inc. in Q4 2018 and held it in 12 quarters.
  • Claro Advisors's Flexion Therapeutics, Inc. position peaked at $467K in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Claro Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.